Business Context and Reporting Period
This Form 8-K Current Report, filed on December 6, 2024, by Septerna, Inc. (SEPN), an emerging growth company incorporated in Delaware, discloses significant changes to executive leadership. The report details the appointment of a new Chief Financial Officer (CFO) and the concurrent departure of the interim CFO, with changes effective January 6, 2025.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Appointment of CFO: The Board appointed Gil M. Labrucherie as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective January 6, 2025.
- Departure of Interim CFO: Ran Xiao resigned as Interim CFO, Principal Financial Officer, and Principal Accounting Officer effective January 6, 2025. Ms. Xiao will remain with the company as Vice President of Finance and Business Operations.
- Compensation Structure: Mr. Labrucherie's annual base salary is set at $485,000 with a target annual bonus of 40% of base salary.
- Equity Grant: Mr. Labrucherie was granted an option to purchase 222,000 shares of common stock, effective February 7, 2025. Vesting is 25% on the first anniversary of his start date, with the remainder vesting monthly over 36 months.
Outlook, Risks, and Contingencies
Severance Arrangements: The filing outlines specific severance benefits for Mr. Labrucherie under the Executive Severance Plan:
- Standard Termination: If terminated without cause or resigns for good reason outside a change in control period, he is entitled to 9 months of base salary and COBRA premium payments for up to 9 months.
- Change in Control Termination: If terminated within a change in control period, he is entitled to a lump sum of 12 months of base salary plus 1.0x the target annual bonus, COBRA premium payments for up to 12 months, and immediate full vesting of time-based equity awards.
Management Commentary: Mr. Labrucherie brings over 25 years of senior leadership experience in the biotechnology sector, including previous CFO roles at Acelyrin, Inc. and Nektar Therapeutics. He also holds a J.D., a B.A., and is a CFA charterholder.
Investor Verification Checklist
- Verify the effective date of the leadership transition (January 6, 2025) against the company's internal calendar and press releases.
- Review the attached Offer Letter (Exhibit 10.1) for complete terms regarding the stock option grant and vesting schedule.
- Confirm the impact of the new CFO's appointment on the company's financial reporting timeline and internal controls.
- Monitor future filings for any updates regarding the vesting of the 222,000 stock options granted to Mr. Labrucherie.